Xencor (XNCR) Competitors

Verona Pharma (NASDAQ:VRNA) and Xencor (NASDAQ:XNCR) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability, earnings and community ranking.

Is VRNA or XNCR more profitable?

Verona Pharma has a net margin of 0.00% compared to Xencor's net margin of -232.77%. Xencor's return on equity of -30.92% beat Verona Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verona Pharma	N/A	-79.54%	-43.49%
Xencor	-232.77%	-30.92%	-21.74%

Which has more risk & volatility, VRNA or XNCR?

Verona Pharma has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500. Comparatively, Xencor has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500.

Do insiders & institutionals believe in VRNA or XNCR?

85.9% of Verona Pharma shares are held by institutional investors. 4.8% of Verona Pharma shares are held by company insiders. Comparatively, 5.2% of Xencor shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Does the media prefer VRNA or XNCR?

In the previous week, Verona Pharma had 7 more articles in the media than Xencor. MarketBeat recorded 8 mentions for Verona Pharma and 1 mentions for Xencor. Verona Pharma's average media sentiment score of 0.76 beat Xencor's score of 0.00 indicating that Verona Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verona Pharma	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xencor	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has stronger valuation and earnings, VRNA or XNCR?

Verona Pharma has higher earnings, but lower revenue than Xencor. Verona Pharma is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verona Pharma	$460K	11,810.27	-$54.37M	-$1.92	-35.40
Xencor	$168.34M	6.54	-$126.09M	-$3.20	-4.92

Do analysts rate VRNA or XNCR?

Verona Pharma presently has a consensus target price of $57.14, indicating a potential downside of 15.92%. Xencor has a consensus target price of $34.88, indicating a potential upside of 121.57%. Given Xencor's higher probable upside, analysts plainly believe Xencor is more favorable than Verona Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verona Pharma	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.13
Xencor	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.13

Does the MarketBeat Community prefer VRNA or XNCR?

Xencor received 177 more outperform votes than Verona Pharma when rated by MarketBeat users. However, 80.84% of users gave Verona Pharma an outperform vote while only 73.44% of users gave Xencor an outperform vote.

Company	Underperform	Outperform
Verona Pharma	Outperform Votes 329 80.84%	Underperform Votes 78 19.16%
Xencor	Outperform Votes 506 73.44%	Underperform Votes 183 26.56%

Summary

Verona Pharma and Xencor tied by winning 8 of the 16 factors compared between the two stocks.